Selective testicular 11beta-HSD inhibitors and methods of use thereof
First Claim
Patent Images
1. A method for increasing male fertility, comprising administering an effective amount of a 11β
- -HSD1 reductase inhibitor to a subject, such that said fertility is increased.
0 Assignments
0 Petitions
Accused Products
Abstract
Methods for increasing and decreasing male fertility using selective 11β-HSD1-dehydrogenase, 11β-HSD1-reductase and 11β-HSD2 dehydrogenase modulating compounds are described.
75 Citations
22 Claims
-
1. A method for increasing male fertility, comprising administering an effective amount of a 11β
- -HSD1 reductase inhibitor to a subject, such that said fertility is increased.
- View Dependent Claims (3, 19, 20)
-
2. A method for increasing testosterone levels in a subject, comprising administering to said subject an effective amount of a 11β
- -HSD1 reductase inhibitor, such that testosterone levels in said subject are increased.
- View Dependent Claims (4, 5, 6, 7, 8, 9, 10)
-
11. A method for decreasing male fertility, comprising administering to a subject an effective amount of a 11β
- -HSD1 dehydrogenase inhibitor, such that said fertility is decreased.
- View Dependent Claims (13, 14, 15, 16, 17, 18)
-
12. A method for decreasing testosterone levels in a subject, comprising administering to a subject an effective amount of a 11β
- -HSD1 dehydrogenase inhibitor, such that testosterone levels in said subject are decreased.
-
21. A pharmaceutical composition comprising an effective amount of 11-keto-progesterone, 11-keto-testosterone, 11-keto-androsterone, 11-keto androstenedione, 11-keto dehydroepiandrostenedione, 3α
- ,5α
-reduced-11-ketoprogesterone, 3α
,5α
-reduced-11-keto-testosterone, 3α
,5α
-reduced-11-keto-androstenedione, 3α
,5α
-tetrahydro-11-dehydro-corticosterone, 3α
, 5α
-reduced-11-keto-androsterone, 3α
, 5α
-reduced-11-keto dehydroepiandrostenedione, 5α
-reduced-11-ketoprogesterone, 5α
-reduced-11-keto-testosterone, 5α
-reduced-11-keto-androstenedione, 5α
-reduced-11-dehydro-corticosterone, 5α
-reduced-11-keto-androsterone, 5α
-reduced-11-keto dehydroepiandrostenedione, 3α
,5β
-tetrahydro-deoxycorticosterone, 3α
,5α
-tetrahydro-progesterone, 3α
,5α
-tetrahydro-testosterone, 3α
,5α
-tetrahydro-deoxycorticosterone, or a pharmaceutically acceptable salt, ester, or prodrug thereof and a pharmaceutically acceptable carrier, wherein said effective amount is effective to increase male fertility.
- ,5α
-
22. A pharmaceutical composition comprising an effective amount of 11β
- -hydroxy testosterone, 11β
-hydroxy androstenedione, 11β
-hydroxy dehydroepiandrostenedione, 11β
-progesterone, chenodeoxycholic acid, 3α
,5α
-reduced-11β
-hydroxy testosterone, 3α
, 5α
-reduced-11-hydroxy androstenedione, 3α
,5α
-reduced-11β
-hydroxy dehydroepiandrostenedione, 3α
,5α
-reduced-corticosterone, 3α
,5α
-reduced-aldosterone, 3α
, 5α
-reduced-11β
-progesterone, 5α
-reduced-11β
-hydroxy testosterone, 5α
-reduced-11β
-hydroxy androstenedione, 5α
-reduced-11β
-hydroxy dehydroepiandrostenedione, 5α
-reduced-11β
-progesterone, 3α
,5β
-reduced-11β
-OH-progesterone, 3α
,5β
-reduced-11β
-OH-testosterone, 3α
,5β
-tetrahydro-deoxycorticosterone, 3α
,5β
-tetrahydro-progesterone, 3α
,5β
-tetrahydro-testosterone, 3α
,5α
-tetrahydro-deoxycorticosterone, 3α
, 5β
-chenodeoxycholic acid or a pharmaceutically acceptable salt, prodrug, or ester thereof and pharmaceutically acceptable carrier, wherein said effective amount is effective to decrease male fertility.
- -hydroxy testosterone, 11β
Specification